Table 4.

Treatment efficacy outcomes.

Characteristic	Abiraterone cohort (n = 86) n (%) or [IQR, 95% CI]	Enzalutamide cohort (n = 148) n (%) or [IQR, 95% CI]	All patients (n = 234) n (%) or [IQR, 95% CI]
PSA50	58 (69)	106 (73)	164 (72)
NA	2 (2)	3 (2)	5 (2)
PSA Δ median	(−83) [−97/-30]	(−85) [−98/-42]	(−85) [−98/−39]
Median FU, mo.	17.5 [11.9-23.1]	14.6 [12.1-17.1]	15.4 [12.1-18.7]
PFS, median, mo.	28.4 [24.2-32.5]	23.1 [18.2-28.1)	26.0 [22.8-29.3]
OS, median, mo.	48.8 [34.3-63.3]	42.3 [39.1-45.4]	48.8 [36.8-60.8]

Abbreviations: CI, confidence intervals; Δ, difference between the PSA baseline and best response values; FU, follow-up; mo., months; NA, not assessable; OS, overall survival; PSA50, decline in the PSA ≥50%; rPFS, radiographic progression-free survival.